The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Open accessAbstract
The immunologic consequences of prolonged infusions of rIL-2 in doses that produce physiologic serum concentrations of this cytokine were investigated. rIL-2 in doses of 0.5-6.0 x 10(6) U/m2 per d (3.3-40 micrograms/m2 per d) was administered by continuous intravenous infusion for 90 consecutive days to patients with advanced cancer. IL-2 concentrations (25 +/- 25 and 77 +/- 64 pM, respectively) that selectively saturate high-affinity IL-2 receptors (IL-2R) were achieved in the serum of patients receiving rIL-2 infusions of 10 micrograms/m2 per d and 30 micrograms/m2 per d. A gradual, progressive expansion of natural killer (NK) cells was seen in the peripheral blood of these patients with no evidence of a plateau effect during the 3 mo of therapy. A preferential expansion of CD56bright NK cells was consistently evident. NK cytotoxicity against tumor targets was only slightly enhanced at these dose levels. However, brief incubation of these expanded NK cells with IL-2 in vitro induced potent lysis of NK-sensitive, NK-resistant, and antibody-coated targets. Infusions of rIL-2 at 40 micrograms/m2 per d produced serum IL-2 levels (345 +/- 381 pM) sufficient to engage intermediate affinity IL-2R p75, which is constitutively expressed by human NK cells. This did not result in greater NK cell expansion compared to the lower dose levels, but did produce in vivo activation of NK cytotoxicity, as evidenced by lysis of NK-resistant targets. There was no consistent change in the numbers of CD56- CD3+ T cells, CD56+ CD3+ MHC-unrestricted T cells, or B cells during infusions of rIL-2 at any of the dosages used. This study demonstrates that prolonged infusions of rIL-2 in doses that saturate only high affinity IL-2R can selectively expand human NK cells for an extended period of time with only minimal toxicity. Further activation of NK cytolytic activity can also be achieved in vivo, but it requires concentrations of IL-2 that bind intermediate affinity IL-2R p75. Clinical trials are underway attempting to exploit the differing effects of various concentrations of IL-2 on human NK cells in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
The Human Hematopoietic Colony-Stimulating Factors
Clark, S. C., & Kamen, R. (1987) · Science · doi:10.1126/science.3296190 · Cited by 1,639
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Self-citationInterleukin-2 augments natural killer cell activity
Henney, C. S., Kuribayashi, K., Kern, D. E., & Gillis, S. (1981) · Nature · doi:10.1038/291335a0 · Cited by 913
Comparative studies of human FcRIII-positive and negative natural killer cells.
Nagler, A., Lanier, L. L., Cwirla, S., & Phillips, J. H. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.10.3183 · Cited by 696
Phillips, J. H., & Lanier, L. L. (1986) · The Journal of experimental medicine · doi:10.1084/jem.164.3.814 · Cited by 684
Lotze, M. T., Matory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, C. A. Y., Custer, M. C., & Rosenberg, S. A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.4.2865 · Cited by 613
Cited by
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Self-citationHuman natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
Self-citationCarson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., & Caligiuri, M. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,092
Self-citationMalek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
Interleukin 15: biology and relevance to human disease
Fehniger, T. A., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.1.14 · Cited by 976
Self-citationFehniger, T. A., Cooper, M. A., Nuovo, G. J., Cella, M., Facchetti, F., Colonna, M., & Caligiuri, M. A. (2003) · Blood · doi:10.1182/blood-2002-09-2876 · Cited by 857
Self-citationZorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 740
Self-citationFehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechser, M., Goodsaid, F., & Caligiuri, M. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4511 · Cited by 652
Self-citationFerlazzo, G., Thomas, D., Lin, S.-L., Goodman, K., Morandi, B., Muller, W. A., Moretta, A., & Münz, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1455 · Cited by 589
Cytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Role of chemokines in the biology of natural killer cells
Robertson, M. J. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.2.173 · Cited by 516
Self-citationCytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
Human natural killer cell development and biology
Farag, S. S., & Caligiuri, M. A. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.10.001 · Cited by 506
Self-citationRomagnani, C., Juelke, K., Falco, M., Morandi, B., D’Agostino, A., Costa, R., Ratto, G., Forte, G., Carrega, P., Lui, G., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.4947 · Cited by 494
What does it take to make a natural killer?
Colucci, F., Caligiuri, M. A., & Di Santo, J. P. (2003) · Nature Reviews Immunology · doi:10.1038/nri1088 · Cited by 493
Self-citationNatural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., & Caligiuri, M. A. (2002) · Blood · doi:10.1182/blood-2002-02-0350 · Cited by 491
Self-citationKovacs, J. A., Baseler, M., Dewar, R. J., Vogel, S., Davey, R. T., Falloon, J., Polis, M. A., Walker, R. E., Stevens, R., Salzman, N. P., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320904 · Cited by 425
Chiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 399
Interleukin-2, Interleukin-15, and Their Roles in Human Natural Killer Cells
Becknell, B., & Caligiuri, M. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86006-1 · Cited by 325
Self-citationNatural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2
Bukowski, R. M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971001)80:7<1198::aid-cncr3>3.0.co;2-h · Cited by 325
NK Cell Compartments and Their Activation by Dendritic Cells
Ferlazzo, G., & Münz, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1333 · Cited by 299
Leong, J. W., Chase, J. M., Romee, R., Schneider, S. E., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.01.006 · Cited by 285
The role of natural killer cells in immune surveillance of cancer
Whiteside, T. L., & Herberman, R. B. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80080-8 · Cited by 280
Interleukin-2 and interleukin-15: immunotherapy for cancer
Fehniger, T. A., Cooper, M. A., & Caligiuri, M. A. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00021-1 · Cited by 280
Self-citationChimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Mehta, R. S., & Rezvani, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00283 · Cited by 259
Burns, L. J., Weisdorf, D. J., DeFor, T. E., Vesole, D. H., Repka, T. L., Blazar, B. R., Burger, S. R., Panoskaltsis-Mortari, A., Keever-Taylor, C. A., Zhang, M.-J., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704086 · Cited by 252
Wang, K. S., Frank, D. A., & Ritz, J. (2000) · Blood · doi:10.1182/blood.v95.10.3183 · Cited by 241
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody
Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., & Pfreundschuh, M. (1997) · Blood · doi:10.1182/blood.v89.6.2042 · Cited by 149
Metadata
- Authors
- Caligiuri, M. A., Murray, C., Robertson, M. J., Wang, E., Cochran, K., Cameron, C., Schow, P., Ross, M. E., Klumpp, T. R., & Soiffer, R. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 123-132
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2095636772
- Cited by
- 269
- References
- 38
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.